|
nafld |
24 |
|
hepatocellular carcinoma |
22 |
|
fatty liver disease |
20 |
|
hbv |
18 |
|
liver transplantation |
18 |
|
obesity |
18 |
|
chronic hepatitis b |
17 |
|
nucleoside analogues |
16 |
|
functional cure |
15 |
|
cap |
14 |
|
liver fibrosis |
14 |
|
liver cancer |
13 |
|
metabolic syndrome |
13 |
|
vcte |
13 |
|
hepatitis b |
12 |
|
intercellular communication |
12 |
|
vaccination |
12 |
|
acute flare |
11 |
|
cirrhosis |
11 |
|
controlled attenuation parameter |
11 |
|
decompensation |
11 |
|
extracellular vesicles |
11 |
|
liver failure |
11 |
|
liver stiffness |
11 |
|
mafld (metabolic associated fatty liver disease) |
11 |
|
meld |
11 |
|
nidogen 1 |
11 |
|
overweight |
11 |
|
population based study |
11 |
|
pre‐metastatic niche |
11 |
|
tumor necrosis factor receptor 1 |
11 |
|
biomarker |
10 |
|
entecavir |
10 |
|
hepatitis b core-related antigen |
10 |
|
m2bpgi |
10 |
|
neutralizing antibody |
10 |
|
proteomics |
10 |
|
tumor microenvironment |
10 |
|
hav |
9 |
|
hcv |
9 |
|
hev |
9 |
|
immigration |
9 |
|
nash |
9 |
|
non-viral liver disease |
9 |
|
tenofovir |
9 |
|
tumorigenesis |
9 |
|
antiviral |
8 |
|
antiviral therapy |
8 |
|
core protein allosteric modulator |
8 |
|
fatty liver |
8 |
|
hcc |
8 |
|
hepatitis b surface antigen |
8 |
|
hepatitis b virus |
8 |
|
nephrotoxicity |
8 |
|
body mass index |
7 |
|
elastography |
7 |
|
hbsag |
7 |
|
hbv dna |
7 |
|
hepatitis b virus infection |
7 |
|
itraq |
7 |
|
liver biopsy |
7 |
|
mafld |
7 |
|
metabolic |
7 |
|
occult hepatitis b |
7 |
|
age |
6 |
|
aspartate aminotransferase |
6 |
|
cure |
6 |
|
feedback signaling |
6 |
|
gastroenterology |
6 |
|
gene silencing |
6 |
|
gitr |
6 |
|
hepaticolenticular degeneration |
6 |
|
hepatitis c |
6 |
|
interleukin‐27 |
6 |
|
mac-2 binding protein glycosylation isomer |
6 |
|
medical sciences |
6 |
|
na therapy |
6 |
|
nucleotide analogue |
6 |
|
pd-1 |
6 |
|
platelet ratio index |
6 |
|
primary biliary cholangitis |
6 |
|
regulatory t cells |
6 |
|
small extracellular vesicles |
6 |
|
spontaneous hbeag seroconversion |
6 |
|
transplantation |
6 |
|
ursodeoxycholic acid |
6 |
|
von willebrand factor |
6 |
|
wfa + -m2bp |
6 |
|
anti-hbs |
5 |
|
cccdna |
5 |
|
core antigen |
5 |
|
core protein |
5 |
|
customized therapies |
5 |
|
deleterious mutations |
5 |
|
dyslipidemia |
5 |
|
hbsag seroclearance |
5 |
|
hbv // chb |
5 |
|
hbx protein |
5 |
|
hepatitis b e antigen |
5 |
|
herbal medicine |
5 |
|
immune response |
5 |
|
liver steatosis |
5 |
|
natural history |
5 |
|
non-alcoholic fatty liver disease |
5 |
|
nucleocapsid |
5 |
|
obese mice |
5 |
|
s-loss |
5 |
|
seroclearance |
5 |
|
statins |
5 |
|
surface antigen |
5 |
|
targeted sequencing |
5 |
|
telbivudine |
5 |
|
transcription |
5 |
|
translation |
5 |
|
viraemia |
5 |
|
virology |
5 |
|
acute liver injury |
4 |
|
adverse effects |
4 |
|
alt |
4 |
|
antisense oligonucleotide |
4 |
|
b cell depletion |
4 |
|
besifovir |
4 |
|
biomarkers |
4 |
|
breast feeding |
4 |
|
carnitine |
4 |
|
carvedilol |
4 |
|
case report |
4 |
|
case series |
4 |
|
chronic kidney disease |
4 |
|
covalently closed circular dna |
4 |
|
covid-19 |
4 |
|
cpams |
4 |
|
cpsh |
4 |
|
crohn's disease |
4 |
|
direct acting antiviral |
4 |
|
dna polymerase inhibitor |
4 |
|
drug interaction |
4 |
|
efficacy |
4 |
|
fanconi syndrome |
4 |
|
finite |
4 |
|
flare |
4 |
|
genome editing |
4 |
|
global elimination |
4 |
|
hbv reactivation |
4 |
|
hbv rna |
4 |
|
health economics |
4 |
|
hepatitis b core antigen |
4 |
|
hepatitis b virus rna |
4 |
|
hepatitis c virus |
4 |
|
humans |
4 |
|
ibrutinib |
4 |
|
immunomodulation |
4 |
|
immunomodulator |
4 |
|
inflammatory bowel disease |
4 |
|
integrated dna |
4 |
|
lactic acidosis |
4 |
|
muscle toxicity |
4 |
|
myopathy |
4 |
|
nadolol |
4 |
|
nirmatrelvir/ritonavir |
4 |
|
nsbb |
4 |
|
nucleos(t)ide analogue |
4 |
|
nucleoside/ nucleotide analogue |
4 |
|
osteomalacia |
4 |
|
peripheral neuropathy |
4 |
|
pharmacokinetics |
4 |
|
prevention |
4 |
|
programmed cell death protein 1 |
4 |
|
propranolol |
4 |
|
protease inhibitor |
4 |
|
renal toxicity |
4 |
|
rna interfering gene silencer |
4 |
|
safety |
4 |
|
surgery |
4 |
|
teratogenecity |
4 |
|
therapeutic vaccine |
4 |
|
treatment outcome |
4 |
|
ulcerative colitis |
4 |
|
varices |
4 |
|
viral entry inhibitor |
4 |
|
viremia |
4 |
|
cancer |
3 |
|
chronic |
3 |
|
chronic hepatitis b virus |
3 |
|
cost–utility analysis |
3 |
|
diagnosis |
3 |
|
direct-acting antiviral agents |
3 |
|
elbasvir/grazoprevir |
3 |
|
hepatocarcinogenesis |
3 |
|
hospitalization |
3 |
|
infection |
3 |
|
intestinal metaplasia |
3 |
|
lymph-node metastasis |
3 |
|
magnifying endoscopy |
3 |
|
medical therapy |
3 |
|
nucleocapsids |
3 |
|
pathogenesis |
3 |
|
prevalence |
3 |
|
subviral particles |
3 |
|
acute drug administration |
2 |
|
adverse outcome |
2 |
|
b12 deficiency |
2 |
|
bacterial clearance |
2 |
|
bacterial growth |
2 |
|
steatosis |
2 |
|
alcohol liver cirrhosis |
1 |
|
antibody titer |
1 |
|
bone density |
1 |
|
child pugh score |
1 |
|
hbeag |
1 |
|
mother to child transmission |
1 |
|
orthodeoxia |
1 |
|
patent foramen ovale |
1 |
|
platypnea |
1 |
|
urinary tract infection |
1 |
|
vertical transmission |
1 |
